Staessen JA, Wendt R, Yu Y-L, et al. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study. Lancet Digit Health 2022; 4: e727–37—In this Article, the affiliation for Matthias Schwab on page 6 of the appendix should have been Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology. This correction has been made as of Dec 15, 2022.
. 2022 Dec 15;5(2):e58. doi: 10.1016/S2589-7500(22)00248-5
Correction to Lancet Digit Health 2022; 4: e727–37
Issue date 2023 Feb.
© 2022 The Author(s). Published by Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9754641 PMID: 36528543
This corrects the article "Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study" in volume 4 on page e727.